2021
Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors
Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas 2021, 50: 890-894. PMID: 34398071, DOI: 10.1097/mpa.0000000000001841.Peer-Reviewed Original ResearchConceptsPeptide receptor radionuclide therapyProgressive diseaseNeuroendocrine tumorsBiopsy-proven neuroendocrine tumorHigher disease control rateMedian progression-free survivalShorter progression-free intervalStanford Cancer CenterDisease control rateMetastatic neuroendocrine tumorsMonths of therapyProgression-free survivalProgression-free intervalReceptor radionuclide therapyBetter patient selectionLarge patient cohortHigh-grade componentHigher disease gradeLow-grade componentRepeat biopsyMedian timePatient selectionInitial pathologyPredictive factorsCancer Center
2020
Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities
Shaheen S, Moradi F, Gamino G, Kunz PL. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Current Treatment Options In Oncology 2020, 21: 25. PMID: 32172368, DOI: 10.1007/s11864-020-0711-9.Peer-Reviewed Original ResearchConceptsPeptide receptor radionuclide therapySomatostatin analoguesToxicity of PRRTOpinion statementNeuroendocrine tumorsMetastatic neuroendocrine tumorsLandscape of treatmentReceptor radionuclide therapyRecent treatment advancesTreatment of NETsPatient selectionNeuroendocrine tumorsTreatment advancesSomatostatin receptorsMinimal response rateRadionuclide therapyResponse rateHeterogenous groupTherapyTumor cellsBiological hallmarksTumorsTreatmentNETsIndolentNeoplasmsNANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Journal Of Nuclear Medicine 2020, 61: 222-227. PMID: 32015164, PMCID: PMC9364765, DOI: 10.2967/jnumed.119.240911.Peer-Reviewed Original Research